Stockscreener 앱 받기
263.51
5.59%
-15.59
시간 외 거래:
263.51
전일 마감가:
$279.10
열려 있는:
$279.1
하루 거래량:
1.49M
Relative Volume:
1.98
시가총액:
$18.93B
수익:
$2.90B
순이익/손실:
$467.20M
주가수익비율:
41.37
EPS:
6.37
순현금흐름:
$306.90M
1주 성능:
+24.95%
1개월 성능:
+19.22%
6개월 성능:
-23.62%
1년 성능:
-4.92%
1일 변동 폭
$261.00
$279.63
1주일 범위
$208.71
$291.00
52주 변동 폭
$187.43
$352.33
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
WST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
263.51 | 20.05B | 2.90B | 467.20M | 306.90M | 6.37 |
|
ISRG
Intuitive Surgical Inc
|
495.86 | 175.16B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
185.32 | 52.63B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
91.86 | 45.46B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
275.16 | 40.10B | 5.02B | 1.31B | 1.56B | 8.91 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio? - Benzinga
Does West Pharmaceutical Services Inc. stock perform well during market downturnsMarket-leading profit generation - jammulinksnews.com
West Pharmaceutical Services: Low Debt, High Profit, And A Waning Destocking Problem - Seeking Alpha
KeyBanc maintains Overweight rating on West Pharmaceutical stock - Investing.com
West Pharmaceutical: Q2 Earnings Snapshot - Erie News Now
S&P 500 Gains and Losses Today: West Pharmaceutical Services Stock Surges; Dow, LKQ Shares Fall - MSN
West Pharmaceutical Lifts Full-Year Forecast After Strong Q2 Performance - MSN
West Pharmaceutical Services Reports Strong Q2 2025 Results - The Globe and Mail
West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors - MSN
De-Risking The Transition From Vial To Drug-Device Combination Product - Med Device Online
West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up - simplywall.st
West Pharmaceutical rises on upbeat results, guidance raise - MSN
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit - MSN
WST: UBS Raises Price Target for West Pharmaceutical Services | WST Stock News - GuruFocus
West Pharmaceutical Services Reports Strong Q2 Earnings, Surpassing ForecastsNews and Statistics - IndexBox
Lead Plaintiff Appointed in West Pharmaceutical Class Action - TradingView
A Quick Look at Today's Ratings for West Pharmaceutical Services(WST.US), With a Forecast Between $325 to $350 - 富途牛牛
West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2025 Earnings Call Transcript - Insider Monkey
West Pharmaceutical Services (WST): A High-Margin Growth Story in the Evolving Pharma Packaging Sector - AInvest
West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates - Yahoo.co
Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks - MSN
Is West Pharmaceutical Services Inc. a good long term investmentHigh-profit capital plays - PrintWeekIndia
West Pharmaceutical Services Inc (WST) Q2 2025 Earnings Call Highlights: Strong Growth in ... By GuruFocus - Investing.com Canada
WST Q2 Deep Dive: High-Value Product Momentum Drives Guidance Increase - TradingView
West Pharmaceutical Services’ Earnings Call Highlights Strong Growth - TipRanks
Stock Movers: West Pharma, Chipotle, Southwest - Bloomberg.com
West Pharmaceutical Services Q2 2025 Earnings Report - MarketBeat
West Pharma Catapults, Making A Bullish Move, On Unexpectedly Strong Earnings - MSN
McMahon Takes Over: What’s Next for West Pharmaceutical? - timothysykes.com
Medical Name Bolts Higher On 'Unexpectedly' Strong Earnings - Investor's Business Daily
U.S. Indexes Finished Mixed Thursday As West Pharmaceutical Svcs Led, Dow Lagged - Barron's
West Pharmaceutical Services raises 2025 revenue guidance to $3.04B–$3.06B as HVP components accelerate - MSN
West Pharma Lifts Forecast As GLP-1 Demand Drives Results - Finimize
West Pharmaceutical’s New CFO: Market Impact? - timothysykes.com
Tesla, IBM Slide; West Pharma Soars Among Thursday’s Market Cap Stock Movers - Investing.com Nigeria
West Pharmaceutical Services Q2 2025: Navigating Contradictions in Growth, Automation, and Revenue Dynamics - AInvest
West Pharmaceutical Services, Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:WST) - Seeking Alpha
West Pharma EPS Jumps 22 Percent in Q2 - The Globe and Mail
West Pharma EPS Jumps 22 Percent in Q2 - The Motley Fool
Why Are West Pharmaceutical Services (WST) Shares Soaring Today - Yahoo Finance
West Pharmaceutical Lifts Forecast As Demand For Drug Components Rises - Finimize
West Pharmaceutical stock price target raised to $350 from $275 at Evercore ISI - Investing.com UK
West Pharmaceutical Services: Leveraging HVP Growth and Regulatory Tailwinds for Long-Term Value Creation - AInvest
West Pharmaceutical Appoints New CFO, Boosting Leadership - StocksToTrade
Strong Growth Prospects and Margin Recovery Justify Buy Rating for West Pharmaceutical Services - TipRanks
West Pharmaceutical rockets on surging GLP-1 demand - Sherwood News
West Pharmaceutical Services Welcomes New CFO, Robert McMahon - timothysykes.com
West Pharma raises annual profit forecast on strong demand for its drug components - whbl.com
West Pharma's Strategic Position in the GLP-1 Boom: A High-Margin Growth Play in a $30 Billion Market - AInvest
West Pharma's Resilient Earnings and Strategic Position in the GLP-1 Boom: A Long-Term Play in the Injectable Drug Supply Chain - AInvest
West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars - Yahoo Finance
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
West Pharmaceutical Services Inc 주식 (WST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Reiss-Clark Cindy | Chief Commercial Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
5,131 |
| MacKay Kimberly Banks | SVP, GC & Corporate Secretary |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
1,605 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
6,823 |
| Winters Chad | VP, Chief Accounting Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
82 |
17,313 |
1,391 |
| Witherspoon Charles | VP & Treasurer |
Feb 18 '25 |
Option Exercise |
211.00 |
66 |
13,864 |
1,319 |
| Green Eric Mark | President, CEO and Board Chair |
Feb 18 '25 |
Option Exercise |
211.00 |
2,461 |
519,269 |
170,369 |
| Witherspoon Charles | VP & Treasurer |
Oct 29 '24 |
Option Exercise |
173.22 |
478 |
82,799 |
1,956 |
| Witherspoon Charles | VP & Treasurer |
Oct 29 '24 |
Sale |
310.40 |
703 |
218,211 |
1,253 |
| Abraham Silji | SVP, Chief Technology Officer |
Oct 29 '24 |
Option Exercise |
0.00 |
458 |
0 |
3,318 |
| Witherspoon Charles | VP & Treasurer |
Aug 19 '24 |
Option Exercise |
102.51 |
529 |
54,228 |
2,507 |
1.56%
자본화:
|
볼륨(24시간):